LGLidia Ghisdal

Lidia Ghisdal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lidia Ghisdal has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Abramowicz

    Department of Nephrology, Antwerp University Hospital, Antwerp, Belgium

    2 shared publications
  • Anne Lemy

    Renal Transplantation Clinic, University of Brussels—Erasme Hospital, Brussels, Belgium

    1 shared publication
  • Joseph Mbaba Mena

    Renal Transplantation Clinic, University of Brussels—Erasme Hospital, Brussels, Belgium

    1 shared publication
  • Judith Racapé

    Department of Biostatistics, School of Public Health, University of Brussels, Brussels, Belgium

    1 shared publication
  • Karl Martin Wissing

    Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB) , Brussels

    1 shared publication
  • Marc Abramowicz

    Human Genetics Unit, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles (ULB), Brussels, Belgium

    1 shared publication

Latest Publications

  • Open Access

    New-Onset Diabetes After Renal Transplantation

    by Lidia Ghisdal, Steven Van Laecke, Marc J. Abramowicz, Raymond Vanholder, Daniel Abramowicz

    New-onset diabetes after transplantation (NODAT) is a serious and frequent metabolic complication after renal transplantation. This entity is currently well defined since the publication of the International Consensus Guidelines in 2003. Here, we review the factors contributing to the risk of NODAT and the strategies related to modifiable factors, with emphasis on practical issues. Recognizing these factors may help clinicians to evaluate prospectively appropriate prevention strategies to minimize the risk of NODAT. Over the past 50 years, the concept of NODAT has evolved in terms of name and definition. Before 2003, de novo diabetes that developed after transplantation was described in various terms, most frequently “posttransplantation diabetes mellitus,” and suffered from a lack of consensus regarding its definition. The most commonly used clinical definition was the requirement of insulin for a minimum period posttransplantation (often 30 days). This definition, however, identified only the most severe cases, leaving out the majority of patients with glucose metabolism disorders. International Consensus Guidelines on NODAT were published in 2003. They recommended that the diagnosis of NODAT should be based on the American Diabetes Association (ADA) criteria for type 2 diabetes published in 2003 (1,2). Since then, a follow-up report from the International Expert Committee further lowered the inferior limit of fasting plasma glucose (FPG) (100 mg/dL) that corresponds to impaired fasting glucose (IFG), based on epidemiologic predictive data (3). In addition, since 2009, the International Expert Committee recommended the use of a standardized A1C assay for diabetes diagnosis (A1C level ≥6.5%), a position that has been endorsed by ADA in 2010 (4). The Expert Committee stated that A1C assay cannot be used in conditions that change red cell turnover. This is the case of end-stage renal disease (ESRD) patients and newly transplanted kidney patients. For instance, the posttransplant period is frequently associated …


  • Open Access

    Thrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation

    by Lidia Ghisdal, Nilufer Broeders, Karl Martin Wissing, Joseph Mbaba Mena, Anne Lemy, Walter Wijns, Olivier Pradier, Vincent Donckier, Judith Racapé, Pierre Vereerstraeten, et al.

    Background. The aim of our study was to evaluate the prevalence of acquired thrombophilic factors in Stage V chronic kidney disease (CKD) patients according to dialysis modality, the rate of correction of these factors 1 month after renal transplantation and their impact on cardiovascular or thromboembolic events at 1 year. Methods. Three hundred and ten patients were prospectively screened for seven thrombophilic factors at transplantation; 215 of them were also assayed 1 month after. All the patients received prophylactic acetylsalicylic acid, started before transplantation. Results. The prevalence of thrombophilic factors was significantly higher in patients under dialysis (n = 289) than in patients not yet on dialysis (n = 21) (74 versus 52.4%; P = 0.03) but was similar in haemodialysis and peritoneal dialysis patients (74.2 versus 73.2%). One month after transplantation, the global prevalence of thrombophilic factors had dropped from 74.4 to 44.7% (P Conclusion. Acquired thrombophilic factors are highly prevalent among Stage V CKD patients. Most thrombophilic factors are corrected 1 month after transplantation.